WALTHAM, Mass., May 26 /PRNewswire/ -- ImmuLogic Pharmaceutical
Corporation (Nasdaq: IMUL) reported today the signing of a license agreement
with Sankyo Co., Ltd. of Tokyo, Japan. The agreement covers certain patents
for recombinant proteins and peptides for the treatment of allergy to Japanese
cedar pollen. The agreement provides for a licensing fee, milestone payments,
and royalties to be paid to ImmuLogic by Sankyo Co., Ltd.
"This is an important validation of our recombinant protein technology,"
said J. Joseph Marr, M.D., President of ImmuLogic Pharmaceutical Corporation.
"Recombinant proteins are a relatively recent development from our research
effort and this licensing arrangement allows ImmuLogic to apply its science to
a significant allergic disease in Japan. It is a pleasure to be associated
with Sankyo in this venture."
ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company,
located in Waltham, MA, focused on the development of reagents for the
diagnosis and treatment of allergies and vaccines for substance abuse. The
Company's press releases are available through Company News On Call by fax at
800-758-5804, ext. 114501, and on the Internet at http://www.prnewswire.com.
This press release contains forward-looking statements that involve a
number of risks and uncertainties. Among the most important factors that
could cause actual results to differ materially from those indicated by such
forward-looking statements are delays in product development, failure to
obtain required regulatory approvals, and the risk factors detailed in the
Company's 10-K for the year ended December 31, 1997.
SOURCE ImmuLogic Pharmaceutical Corporation
 back to top
Company News On-Call: http://www.prnewswire.com or
fax, 800-758-5804, ext. 114501
CONTACT:
Investor Relations at ImmuLogic
Pharmaceutical Corporation, 781-466-6000
|
